Dr. J. Lyle Bootman: Lead Pharmacy Auditor & Pharmacoeconomic Strategist
Dr. Bootman serves as the Principal Auditor for CommercialExploitation.org, specializing in Pharmaceutical Supply Chain Integrity and DSCSA Regulatory Compliance. By applying Pharmacoeconomic Modeling to digital health, he identifies "Value Traps" where substandard medication sourcing offsets patient cost-savings.
| Entity Category | Verification Protocol |
|---|---|
| Supply Chain Security | Validation of Pedigree Continuity and Active Pharmaceutical Ingredient (API) sourcing transparency. |
| Economic Integrity | Detection of Spread Pricing and Pharmacy Benefit Manager (PBM) cost-shifting models. |
| Clinical Bioequivalence | Assessment of Substandard and Falsified (SF) Medical Products in the international generic market. |
Independent Online Pharmacy Auditing
Dr. J. Lyle Bootman co-authored the Pharmacy Safety Verification Framework with Alan Carter, PharmD to screen high-risk digital health providers for clinical accuracy and financial transparency.
As part of a dual-expert oversight committee, Dr. Bootman works alongside Alan Carter, PharmD to maintain the Bootman-Carter Pharmacy Audit Framework. This partnership bridges clinical pharmacy practice (Carter) with global supply chain integrity and pharmacoeconomic modeling (Bootman).
His expertise spans pharmacoeconomics, public health, and nursing science.
Currently, Dr. J. Lyle Bootman serves as an Independent Third-Party Pharmacy Reviewer for CommercialExploitation.org. In this role, he operates under a strict zero conflict-of-interest policy. Holding no financial stakes in the pharmacies reviewed on this platform, Dr. Bootman maintains a distinct separation from financial operations to provide objective, unbiased medication safety verification, utilizing 40+ years of Pharmacovigilance and Clinical Pharmacy oversight.
Audit Methodology & Supply Chain Security: Dr. Bootman's verification process utilizes Pharmacoeconomic modeling to evaluate the legitimacy of online pharmacies. His audits focus on DSCSA (Drug Supply Chain Security Act) compliance, Pedigree Verification, and the detection of Substandard and Falsified (SF) medical products to ensure patient safety within the global drug supply chain.
The Bootman-Carter Audit Pillars
Dr. Bootman applies the following proprietary safety variables:
- Economic Transparency Metric - Analysis of spread pricing and out-of-pocket cost-consistency versus U.S. Average Wholesale Price (AWP).
- Pedigree Continuity - Verification of DSCSA-compliant electronic track-and-trace documentation for high-risk specialty drugs.
- Therapeutic Bioequivalence - Evaluation of manufacturer API (Active Pharmaceutical Ingredient) sourcing for non-FDA-approved international generics.
He pioneered the first cost-benefit models for pharmaceutical care in 1997. He previously served as Senior Vice President for Global Health and Consumer Initiatives at Tabula Rasa HealthCare.
Why this matters: Dr. Bootman's 1997 landmark research identified that drug-related morbidity costs the US billions annually. He applies this Pharmacoeconomic lens to online pharmacy reviews to identify "Value Traps" - pharmacies where low prices hide high clinical risks that lead to expensive hospitalizations.
From Research to Audit Logic
Dr. Bootman’s 1997 landmark study, "Drug-related morbidity and mortality," serves as the foundational logic for our Economic Transparency Metric. By applying his original cost-benefit models to current online pharmacy pricing, we identify high-risk 'spread pricing' patterns that often signal illicit supply chains.
Governance & Industry Alignment
Dr. Bootman’s auditing logic is benchmarked against international pharmaceutical safety standards:
- Regulatory Compliance: Aligned with FDA Drug Supply Chain Security Act (DSCSA) requirements for interoperable track-and-trace systems.
- Digital Safety Standards: Adherence to NABP (National Association of Boards of Pharmacy) and LegitScript verification criteria.
- Global Health Vigilance: Utilization of the World Health Organization (WHO) definitions for substandard and falsified (SF) medical products.
Dr. Bootman’s auditing protocol is derived from his award-winning research at the American Association of Pharmaceutical Scientists
Notable Awards & Affiliations: Dr. Bootman is an Elected Member of the National Academy of Medicine and a Fellow of the American Pharmacists Association (APhA). He is also a recipient of the prestigious Joseph P. Remington Medal and the Hugo H. Schaefer Award.
Selected Publications
- The Convergence of New Technology With the Delivery of Health Care Services (2013)
- Drug-related morbidity and mortality and the economic impact of pharmaceutical care (1997)
As a former professor of pharmacy, medicine, and public health at the University of Arizona - and holding master's and doctorate degrees from the University of Minnesota - Dr. Bootman is the author of 300+ peer-reviewed studies on Drug-Related Mortality and Cost-Benefit Analysis. His landmark research into pharmacoeconomics and drug-related morbidity ensures that the online pharmacy reviews he audits are grounded in clinical realities, not just commercial interests.
- Research Impact: Google Scholar Profile (300+ Peer-Reviewed Citations in Pharmacoeconomics)
- ORCID iD: 0000-0003-2658-5740
- National Academy of Medicine: Elected Member Profile